(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676316/
(2) https://www.nature.com/articles/s41392-021-00536-0/figures/1
Collectively, these results confirmed the capability of SARS-CoV-2 to escape from antibodies, especially the ACE2-competing antibodies, by acquiring resistance mutations in RBD. Such escape mutations can occur within the binding epitopes of antibodies, or regions away from antibody epitopes but may affect immunogenicity of RBD and render antibodies ineffective (Fig. 1f). Notably, the ACE2-competing antibodies constitute the majority of anti-RBD antibodies elicited by SARS-CoV-2 infection or vaccination. Therefore, our findings highlight the importance of continuously monitoring RBD natural mutations and evaluating their impact on antibody recognition of SARS-CoV-2, which may help guide the development and implementation of therapeutic antibodies and vaccines against SARS-CoV-2.
(3) Ilmoitus kaksoismutantti variaatiosta https://www.biorxiv.org/content/10.1101/2020.03.15.991844v6
V367F + D614G maaliskuussa 2020.
(4) E484K mutaation merkityksestä artikkeli
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00068-9/fulltext
5) neljä päivää sitten tulut artikkeli Sars-2 mutaatioista ja varianteista: https://viralzone.expasy.org/9556
Inga kommentarer:
Skicka en kommentar